No Data
Trump's Cannabis Reform: Mike Tyson, Weldon Angelos Say President Can Get It Done
Express News | FDA Adds Boxed Warning About Anaphylaxis With Multiple Sclerosis Medicine Glatiramer Acetate (Copaxone, Glatopa)
Teva Pharmaceutical Industries (TEVA.US) has applied for the market launch of Remanani monoclonal antibody injection in China, which can significantly improve the migraine symptoms of patients.
On January 22, the official website of the China National Medical Products Administration's Center for Drug Evaluation (CDE) announced that the application for marketing of the new 3.1 class drug Remanacumab injection, filed by Teva Pharmaceutical Industries (TEVA.US), has been accepted.
Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $30
Institutional Investors Have a Lot Riding on Teva Pharmaceutical Industries Limited (NYSE:TEVA) With 68% Ownership
Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday
Mangkawat : red day but its still stable
Jaguar8 OP Mangkawat : Nothing big news for me on this one unless it comes with a monetary award
Mangkawat Jaguar8 OP : how about $BioLine Rx (BLRX.US)$ bioline rx. any news ? drop and drop.
Jaguar8 OP Mangkawat : It made an offering days ago
Mangkawat Jaguar8 OP : but price look like on risk to be delist. still below $1 .
View more comments...